GE HealthCare's 1.5x Leverage, $1.7B Free Cash Flow Bodes Well for $105–$120 Valuation
GE HealthCare generated $1.5–1.7 billion in free cash flow and cut net leverage to 1.5x EBITDA, funding its $2.3 billion Intelerad deal while strengthening its balance sheet. Trading at about 16x forward earnings, shares imply fair value of $105–$120 near term and $200 longer term as recurring revenue climbs above 60%.
1. Improved Financial Position
GE HealthCare has used disciplined cash generation to produce $1.5–1.7 billion in annual free cash flow, reducing net leverage to approximately 1.5x EBITDA. This deleveraging has enabled the company to complete its $2.3 billion Intelerad acquisition without compromising balance sheet strength.
2. Valuation Analysis
Shares trade near 16x forward earnings, a discount to medtech peers such as Siemens Healthineers. Valuation models, including discounted cash flow and sum-of-the-parts, suggest fair value between $105 and $120 in the near term and a longer-term target of $200 as margins expand.
3. Recurring Revenue Strategy
The company aims to boost recurring revenue above 60% of total sales by expanding digital and service offerings. Management projects EPS growth to $8.50–$9.50 by 2030, driven by margin expansion and compound annual growth in equipment and software.
4. Technical and Analyst Perspectives
Technical support is indicated around $75–$80, with constructive institutional positioning. Consensus analyst targets remain below intrinsic valuations, implying potential for upgrades as execution on cash conversion and recurring revenue targets progresses.